8-K: TerrAscend Reports Q4 & FY 2025 Results, Boosts Cash Flow

TerrAscend Corp. announced its fourth quarter and full year 2025 financial results, highlighting strong cash flow generation and strategic market focus.

Summary

• Net Revenue for Q4 2025 was $66.1 million, a 1.6% sequential increase from Q3 2025's $65.1 million.
• Full Year 2025 Net Revenue was $260.6 million, a 2.8% decrease from $268.1 million in 2024.
• Gross Profit Margin from continuing operations was 52.1% for Q4 2025 and 52.3% for FY 2025, an improvement from 50.7% in 2024.
• GAAP Net Loss from continuing operations was $0.5 million for Q4 2025, a significant improvement from a $9.9 million loss in Q3 2025.
• Full Year 2025 GAAP Net Loss from continuing operations increased to $24.5 million from $20.9 million in 2024.
• Adjusted EBITDA from continuing operations was $16.7 million for Q4 2025 and $67.8 million for FY 2025.
• Net Cash provided from continuing operations was $8.3 million for Q4 2025 and $33.9 million for FY 2025, marking the 14th consecutive quarter of positive cash flow.
• Free Cash Flow was $6.6 million for Q4 2025 and $25.3 million for FY 2025, marking the 10th consecutive quarter of positive free cash flow.
• The company strengthened retail operations by closing the Union Chill transaction, adding a fourth dispensary in New Jersey.
• An exclusive licensing agreement with Tyson 2.0 was entered for manufacturing and distribution in Maryland and Pennsylvania, with launch expected this month.
• The strategic exit from the Michigan market is significantly advanced, with the sale of the majority of assets completed and net proceeds used to reduce debt.
• A $79 million non-dilutive refinancing of existing debt was executed, along with an additional uncommitted term loan facility of up to $35 million for strategic M&A.
• The company repurchased 1,117,500 shares in 2025 through its normal course issuer bid at a weighted average price of $0.44 USD per share.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive report, reflecting strong operational cash flow and strategic execution despite some top-line and EBITDA declines, indicating a focus on long-term profitability and market positioning.

Positives

• Achieved 14th consecutive quarter of positive Net Cash provided from continuing operations, totaling $8.3 million in Q4 2025.
• Recorded 10th consecutive quarter of positive Free Cash Flow, reaching $6.6 million in Q4 2025.
• Q4 2025 GAAP Net Loss from continuing operations significantly improved to $0.5 million from a $9.9 million loss in Q3 2025.
• Full Year 2025 Gross Profit Margin from continuing operations improved to 52.3% from 50.7% in 2024.
• Successfully completed a $79 million non-dilutive debt refinancing, with no material debt maturities until late 2028.
• Secured an additional uncommitted term loan facility of up to $35 million for future strategic M&A.
• Strategic exit from the Michigan market is largely complete, with proceeds utilized to reduce existing debt.
• Strong retail performance in core Northeast markets, with several Apothecarium stores ranking in the top 10 or 20 in New Jersey, Maryland, and Pennsylvania.
• Expanded into Ohio with the acquisition of Ratio Cannabis LLC assets.
• Entered an exclusive licensing agreement with Tyson 2.0 for Maryland and Pennsylvania, expected to launch this month.

Negatives

• Full Year 2025 Net Revenue declined to $260.6 million from $268.1 million in 2024.
• Full Year 2025 GAAP Net Loss from continuing operations increased to $24.5 million from $20.9 million in 2024.
• Full Year 2025 Adjusted EBITDA from continuing operations decreased to $67.8 million from $70.2 million in 2024.
• Full Year 2025 Net Cash provided from continuing operations decreased to $33.9 million from $46.2 million in 2024, partly due to higher net tax payments of $9.4 million in 2025 compared to net tax refunds of $5.0 million in 2024.
• Full Year 2025 Free Cash Flow decreased to $25.3 million from $39.4 million in 2024.
• Wholesale revenue declined 9.4% year-over-year for FY 2025.
• Adjusted EBITDA Margin from continuing operations slightly decreased for both Q4 2025 (25.2% vs 26.1% in Q3 2025) and FY 2025 (26.0% vs 26.2% in FY 2024).

Risks

• Significant legal restrictions and regulations govern the cannabis industry in the United States, as cannabis remains a Schedule I drug under federal law, making it illegal to cultivate, distribute, or possess.
• Financial transactions involving proceeds generated by, or intended to promote, cannabis-related business activities in the United States may form the basis for prosecution under applicable US federal money laundering legislation.
• Strict compliance with state laws regarding cannabis will neither absolve TerrAscend of liability under U.S. federal law nor provide a defense to any federal proceeding.
• The enforcement of federal laws in the United States is a significant risk that could adversely affect TerrAscend's operations and financial performance.
• Forward-looking information is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially, including current and future market conditions and changes in the regulatory environment.

Future Outlook

Management expects sustainable growth and shareholder value in 2026 and beyond, driven by a disciplined M&A strategy, a strong balance sheet, consistent free cash flow generation, and regulatory momentum at both state and federal levels. The company plans to launch Tyson 2.0 products in Maryland and Pennsylvania this month.

Management Comments

• "I am pleased to report another period of strong performance in our core Northeast markets of New Jersey, Maryland, and Pennsylvania." Jason Wild, Executive Chairman.
• "For the full year, we generated approximately $261 million in revenue, $68 million in Adjusted EBITDA, $34 million in positive operating cash flow and $25 million in free cash flow from continuing operations." Jason Wild, Executive Chairman.
• "Importantly, for the fourth quarter and full year periods our gross margin from continuing operations was above 52% and our Adjusted EBITDA margin from continuing operations was above 25%." Jason Wild, Executive Chairman.
• "We remain disciplined in our M&A strategy focusing solely on accretive transactions that align with our strategic goals." Jason Wild, Executive Chairman.
• "With a strong balance sheet, no material debt maturities until late 2028, consistent free cash flow generation, and regulatory momentum at both the state and federal levels, we believe TerrAscend is well equipped to deliver sustainable growth and drive shareholder value in 2026 and beyond." Jason Wild, Executive Chairman.

Industry Context

StockSavvy.ai notes that TerrAscend's focus on core Northeast markets (New Jersey, Maryland, Pennsylvania) and strategic exit from Michigan aligns with a broader industry trend among multi-state operators (MSOs) to optimize portfolios and concentrate resources on high-growth, high-margin states. The expansion into Ohio and the licensing agreement with Tyson 2.0 indicate a strategy to deepen market penetration and leverage brand partnerships in key regions, a common tactic for increasing market share in a competitive and evolving cannabis landscape.

Comparison to Industry Standards

• StockSavvy.ai observes that TerrAscend's consistent positive cash flow from operations (14 consecutive quarters) and free cash flow (10 consecutive quarters) are strong indicators of operational efficiency and financial discipline, often outperforming many smaller or less established MSOs in the fragmented U.S. cannabis market which frequently struggle with profitability and cash generation.
• The gross profit margin above 52% for both Q4 and FY 2025 is competitive within the cannabis industry, often exceeding the margins of companies heavily reliant on wholesale or in highly saturated markets.
• The strategic debt refinancing and securing of an M&A facility demonstrate access to capital and financial structuring capabilities comparable to more mature companies, distinguishing TerrAscend from peers facing tighter credit markets.

Stakeholder Impact

• Shareholders: Potential for increased shareholder value through strategic M&A, share repurchases, and sustained free cash flow generation.
• Employees: Integration of Ratio Cannabis into operations and expansion in core markets may create new opportunities, while the Michigan exit could impact employees in that region.
• Customers: Expanded retail footprint in New Jersey and new product offerings (Tyson 2.0) in Maryland and Pennsylvania aim to enhance product selection and accessibility.
• Creditors: Debt refinancing and no material debt maturities until late 2028 provide financial stability and reduced short-term risk.

Next Steps

• Launch Tyson 2.0 products across Maryland and Pennsylvania this month (March 2026).
• Continue to evaluate opportunities to acquire high-quality stores in Ohio.
• Deliver sustainable growth and drive shareholder value in 2026 and beyond.
• Repurchase common shares under the normal course issuer bid until August 2026.

Key Dates

Recommendation

While TerrAscend demonstrates strong operational cash flow and strategic discipline, the slight declines in full-year revenue and Adjusted EBITDA, coupled with the inherent federal regulatory risks in the U.S. cannabis market, suggest a "hold" position. The company is executing a clear strategy to optimize its portfolio and enhance profitability, but the overall market conditions and regulatory environment warrant a cautious approach until sustained growth in core markets is more evident.

Keywords

Cannabis, Multi-State Operator, MSO, TerrAscend, TSNDF, Financial Results, Q4 2025, FY 2025, Earnings, Revenue, EBITDA, Cash Flow, New Jersey, Maryland, Pennsylvania, Ohio, Michigan, Tyson 2.0, Debt Refinancing, Share Repurchase